Biogen Inc.

270.03+4.86+1.83%Vol 968.18K1Y Perf 24.49%
Mar 24th, 2023 16:00 DELAYED
BID265.44 ASK271.50
Open265.44 Previous Close265.17
Pre-Market- After-Market270.15
 - -  0.12 0.04%
Target Price
308.58 
Analyst Rating
Moderate Buy 1.74
Potential %
14.28 
Finscreener Ranking
★★★     50.14
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★+     54.05
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★★★     58.14
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
66.44 
Earnings Rating
Neutral
Market Cap39.02B 
Earnings Date
2nd May 2023
Alpha-0.00 Standard Deviation0.10
Beta0.39 

Today's Price Range

263.15271.36

52W Range

187.16311.88

5 Year PE Ratio Range

7.1032.60

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Buy
Performance
1 Week
2.61%
1 Month
0.00%
3 Months
-3.27%
6 Months
36.53%
1 Year
24.49%
3 Years
-5.25%
5 Years
3.81%
10 Years
53.23%

TickerPriceChg.Chg.%
BIIB270.034.86001.83
AAPL160.251.32000.83
GOOG106.08-0.1850-0.17
MSFT280.572.91001.05
XOM103.530.12000.12
WFC36.23-0.3800-1.04
JNJ152.651.52001.01
FB196.640.99000.51
GE91.37-0.2200-0.24
JPM124.91-1.9300-1.52
 
ProfitabilityValueIndustryS&P 500US Markets
76.20
35.20
40.40
37.50
31.62
RevenueValueIndustryS&P 500US Markets
7.63B
52.98
-7.70
-0.75
Earnings HistoryEstimateReportedSurprise %
Q04 20223.514.0515.38
Q03 20224.134.7715.50
Q02 20224.095.2528.36
Q01 20224.413.62-17.91
Q04 20213.323.392.11
Q03 20214.154.7714.94
Q02 20214.575.6824.29
Q01 20215.065.345.53
Earnings Per EndEstimateRevision %Trend
12/2022 QR3.41-3.13Negative
12/2022 FY17.033.34Positive
3/2023 QR4.022.03Positive
12/2023 FY15.830.13Positive
Next Report Date2nd May 2023
Estimated EPS Next Report3.32
Estimates Count23
EPS Growth Next 5 Years %10.00
Volume Overview
Volume968.18K
Shares Outstanding144.49K
Shares Float129.76M
Trades Count25.52K
Dollar Volume260.08M
Avg. Volume873.57K
Avg. Weekly Volume805.53K
Avg. Monthly Volume859.88K
Avg. Quarterly Volume955.29K

Biogen Inc. (NASDAQ: BIIB) stock closed at 270.03 per share at the end of the most recent trading day (a 1.83% change compared to the prior day closing price) with a volume of 968.18K shares and market capitalization of 39.02B. Is a component of S&P 500, NASDAQ 100, Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 9100 people. Biogen Inc. CEO is Michel Vounatsos.

The one-year performance of Biogen Inc. stock is 24.49%, while year-to-date (YTD) performance is -2.49%. BIIB stock has a five-year performance of 3.81%. Its 52-week range is between 187.16 and 311.88, which gives BIIB stock a 52-week price range ratio of 66.44%

Biogen Inc. currently has a PE ratio of 14.20, a price-to-book (PB) ratio of 3.15, a price-to-sale (PS) ratio of 5.19, a price to cashflow ratio of 17.10, a PEG ratio of 2.32, a ROA of 12.73%, a ROC of 16.54% and a ROE of 26.51%. The company’s profit margin is 31.62%, its EBITDA margin is 40.40%, and its revenue ttm is $7.63 Billion , which makes it $52.98 revenue per share.

Of the last four earnings reports from Biogen Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $3.32 for the next earnings report. Biogen Inc.’s next earnings report date is 02nd May 2023.

The consensus rating of Wall Street analysts for Biogen Inc. is Moderate Buy (1.74), with a target price of $308.58, which is +14.28% compared to the current price. The earnings rating for Biogen Inc. stock is Neutral (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Biogen Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Biogen Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 10.50, ATR14 : 6.27, CCI20 : 52.73, Chaikin Money Flow : 0.00, MACD : -2.97, Money Flow Index : 47.30, ROC : 2.67, RSI : 51.65, STOCH (14,3) : 91.97, STOCH RSI : 1.00, UO : 54.81, Williams %R : -8.03), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Biogen Inc. in the last 12-months were: Ginger Gregory (Option Excercise at a value of $0), Ginger Gregory (Sold 5 610 shares of value $1 683 617 ), Michael R. Mcdonnell (Option Excercise at a value of $0), Nicole Murphy (Option Excercise at a value of $0), Priya Singhal (Option Excercise at a value of $0), Rachid Izzar (Option Excercise at a value of $0), Robin C. Kramer (Option Excercise at a value of $0), Susan H. Alexander (Option Excercise at a value of $0), Susan H. Alexander (Sold 5 532 shares of value $1 552 832 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
16 (59.26 %)
16 (59.26 %)
15 (55.56 %)
Moderate Buy
2 (7.41 %)
2 (7.41 %)
3 (11.11 %)
Hold
9 (33.33 %)
9 (33.33 %)
9 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.74
Moderate Buy
1.74
Moderate Buy
1.76

Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

CEO: Michel Vounatsos

Telephone: +1 617 679-2000

Address: 225 Binney Street, Cambridge 02142, MA, US

Number of employees: 9 100

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

33%67%

Bearish Bullish

56%44%

Bearish Bullish

65%35%

Bearish Bullish

59%41%

TipRanks News for BIIB

Thu, 23 Mar 2023 12:30 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Regeneron (REGN) and Alcon (ALC)

- TipRanks. All rights reserved.

Thu, 23 Mar 2023 10:40 GMT Analysts Top Healthcare Picks: Biogen (BIIB), Applied DNA Sciences (APDN)

- TipRanks. All rights reserved.

Thu, 23 Mar 2023 10:35 GMT Biogen (BIIB) Receives a Hold from BTIG

- TipRanks. All rights reserved.

Tue, 21 Mar 2023 12:50 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Danaher (DHR) and Blueprint Medicines (BPMC)

- TipRanks. All rights reserved.

Mon, 20 Mar 2023 23:00 GMT Analysts Conflicted on These Healthcare Names: Biogen (BIIB), Sarepta Therapeutics (SRPT) and G1 Therapeutics (GTHX)

- TipRanks. All rights reserved.

Tue, 14 Mar 2023 10:11 GMT Analysts Opinions Are Mixed on These Healthcare Stocks: Biogen (BIIB), Illumina (ILMN) and Arcutis Biotherapeutics (ARQT)

- TipRanks. All rights reserved.

Mon, 13 Mar 2023 18:30 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Crinetics Pharmaceuticals (CRNX) and 89bio (ETNB)

- TipRanks. All rights reserved.

Fri, 17 Feb 2023 15:05 GMT Biogen (BIIB) Gets a Buy from SVB Securities

- TipRanks. All rights reserved.

Fri, 17 Feb 2023 04:50 GMT Analysts Have Conflicting Sentiments on These Healthcare Companies: Biogen (BIIB), SAGE Therapeutics (SAGE) and Karyopharm Therapeutics (KPTI)

- TipRanks. All rights reserved.

Thu, 16 Feb 2023 16:40 GMT Analysts Offer Insights on Healthcare Companies: Amedisys (AMED), Biogen (BIIB) and Waters (WAT)

- TipRanks. All rights reserved.

Thu, 16 Feb 2023 09:55 GMT Biogen (BIIB) Gets a Buy from Morgan Stanley

- TipRanks. All rights reserved.

Wed, 15 Feb 2023 13:30 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and ChitogenX (OtherCHNXF)

- TipRanks. All rights reserved.

Wed, 15 Feb 2023 13:20 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB), Applied DNA Sciences (APDN) and Provention Bio (PRVB)

- TipRanks. All rights reserved.

Thu, 09 Feb 2023 13:40 GMT Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Envista Holdings (NVST)

- TipRanks. All rights reserved.

News

Stocktwits